MAGNIFY

The Next Generation Incubator at CNSI

Ferrologix uses magnetic nanotechnology to accelerate research and manufacturing of cellular therapies.

Market:

Emerging cellular therapies have shown incredible potential as “living drugs” that achieve personalized treatments in a variety of healthcare fields and represent a growing market of $1.8 billion with a 10% CAGR. Interviews with over 235 clinicians, researchers, and industry experts identified cell purification, transfection/transduction, and QC/Release as key focus areas for cellular therapies. Ferrologix is developing single use cartridge based platforms in each of these application areas.

Technology:

Ferrologix’ core technology, known as “ratcheting cytometry,” employs an array of inexpensive magnetic micropillars patterned onto a plastic substrate to form a single use cartridge. When subjected to a rotating magnetic field cells which have been labeled with a magnetic antibody can be precisely manipulated in a massively parallelized format. Various chip designs can execute a variety of functions such as rapid cell purification, quantitative separation based on surface expression, and cell co-localization with transduction/transfection reagents.

Advantages:

  • Quick: 10X faster than current magnetic purification platforms
  • Quantitative: Separate specific cell subtypes
  • Closed: Aseptic operation to meet GMP standards
  • Continuous: Compatible with large volumes and cell quantities

Development Stage:

  • Prototype: Currently have several operational prototypes and have initiated beta testing in partnering labs and potential customers.

Patents Pending:

  • PCT Application: WO2016100234A1

Select Publications:

Company Contact:

Website: www.ferrologix.com
Contact: Coleman Murray, 760-533-2826